Showing posts with label bone marrow stem cells. Show all posts
Showing posts with label bone marrow stem cells. Show all posts
Thursday, July 25, 2013
New Stem Cell Gene Therapy Gives Hope to Prevent Inherited Neurological Disease
Source: University of Manchester
Date: 25 July 2013
Summary:
Scientists from The University of Manchester have used stem cell gene therapy to treat a fatal genetic brain disease in mice for the first time. The method was used to treat Sanfilippo – a fatal inherited condition which causes progressive dementia in children – but could also benefit several neurological, genetic diseases. Researchers behind the study, published in the journal Molecular Therapy this month, are now hoping to bring a treatment to trial in patients within two years.
Wednesday, July 03, 2013
HIV Positive Men Show No Signs of HIV after Bone Marrow Transplant and Discontinuation of Anti-Retroviral Therapy
Source: Brigham and Women's Hospital
Date: July 3, 2013
Summary:
Boston, MA - Two Brigham and Women's Hospital patients with longstanding HIV infections who underwent bone marrow transplants have stopped anti-retroviral therapy and have no detectable HIV in their blood cells. One patient stopped anti-retroviral therapy 15 weeks ago, the other stopped 7 weeks ago. These new findings will be presented on July 3, 2013 at the International AIDS Society Conference (IAS 2013) in Kuala Lumpur, Malaysia by Timothy Henrich, MD and Daniel Kuritzkes, MD, physician-researchers in the Division of Infectious Diseases at Brigham and Women's Hospital.
Monday, December 03, 2012
Stem Cell-Derived Dopaminergic Neurons Rescue Motor Defects in Parkinsonian Monkeys
Source: Journal of Clinical Investigation
Date December 3, 2012
Researchers have derived dopaminergic neurons from bone marrow stem cells in monkeys.
Parkinson's disease is a degenerative disorder of the central nervous system that is characterized by tremors, rigidity, slowness of movement, and difficulty walking. It is caused by loss of the neurons that produce the neurotransmitter dopamine (known as dopaminergic neurons). One of the primary goals in Parkinson's disease research is to develop a replacement for dopaminergic neurons.
In a new study, researchers led by Takuya Hayashi at the RIKEN Center for Molecular Imaging Science in Kobe, Japan, derived dopaminergic neurons from bone marrow stem cells in monkeys. The cells were retrieved during a standard bone marrow aspiration and then treated with growth factors that directed the stem cells to become dopaminergic neurons. The monkeys that donated the stem cells were treated with a chemical to induce Parkinson's disease and then received a transplant of the new dopaminergic neurons that had been derived from their own bone marrow stem cells. Monkeys that received the transplant showed significant improvement in motor defects.
This study demonstrates that dopaminergic neurons derived from adult bone marrow stem cells can be safely used to improve motor function in Parkinson's disease in monkeys.
The research is published in the Journal of Clinical Investigation.
Parkinson's disease is a degenerative disorder of the central nervous system that is characterized by tremors, rigidity, slowness of movement, and difficulty walking. It is caused by loss of the neurons that produce the neurotransmitter dopamine (known as dopaminergic neurons). One of the primary goals in Parkinson's disease research is to develop a replacement for dopaminergic neurons.
In a new study, researchers led by Takuya Hayashi at the RIKEN Center for Molecular Imaging Science in Kobe, Japan, derived dopaminergic neurons from bone marrow stem cells in monkeys. The cells were retrieved during a standard bone marrow aspiration and then treated with growth factors that directed the stem cells to become dopaminergic neurons. The monkeys that donated the stem cells were treated with a chemical to induce Parkinson's disease and then received a transplant of the new dopaminergic neurons that had been derived from their own bone marrow stem cells. Monkeys that received the transplant showed significant improvement in motor defects.
This study demonstrates that dopaminergic neurons derived from adult bone marrow stem cells can be safely used to improve motor function in Parkinson's disease in monkeys.
The research is published in the Journal of Clinical Investigation.
Sunday, September 02, 2012
Scientists Discover 'Missing Link' Between Stem Cells and the Immune System
Source: University of California, Los Angeles (UCLA), Health Sciences
Date: September 2, 2012
Summary:
UCLA researchers have discovered a type of cell that is the "missing link" between bone marrow stem cells and all the cells of the human immune system, a finding that will lead to a greater understanding of how a healthy immune system is produced and how disease can lead to poor immune function. The studies were done using human bone marrow, which contains all the stem cells that produce blood during postnatal life.
Understanding the process of normal blood formation in human adults is a crucial step in shedding light on what goes wrong during the process that results in leukemias, or cancers of the blood. The study appears Sept. 2 in the early online edition of Nature Immunology.
Date: September 2, 2012
Summary:
UCLA researchers have discovered a type of cell that is the "missing link" between bone marrow stem cells and all the cells of the human immune system, a finding that will lead to a greater understanding of how a healthy immune system is produced and how disease can lead to poor immune function. The studies were done using human bone marrow, which contains all the stem cells that produce blood during postnatal life.
Understanding the process of normal blood formation in human adults is a crucial step in shedding light on what goes wrong during the process that results in leukemias, or cancers of the blood. The study appears Sept. 2 in the early online edition of Nature Immunology.
Tuesday, July 03, 2012
Adult Stem Cells from Bone Marrow: Cell Replacement/Tissue Repair Potential in Adult Bone Marrow Stem Cells in Animal Model
Source: University of Maryland Medical Center
Date: July 3, 2012
Summary:
Baltimore, MD – Researchers from the University of Maryland School of Medicine report promising results from using adult stem cells from bone marrow in mice to help create tissue cells of other organs, such as the heart, brain and pancreas -- a scientific step they hope may lead to potential new ways to replace cells lost in diseases such as diabetes, Parkinson's or Alzheimer's. The research in collaboration with the University of Paris Descartes is published online in the June 29, 2012 edition of Comptes Rendus Biologies, a publication of the French Academy of Sciences.
Date: July 3, 2012
Summary:
Baltimore, MD – Researchers from the University of Maryland School of Medicine report promising results from using adult stem cells from bone marrow in mice to help create tissue cells of other organs, such as the heart, brain and pancreas -- a scientific step they hope may lead to potential new ways to replace cells lost in diseases such as diabetes, Parkinson's or Alzheimer's. The research in collaboration with the University of Paris Descartes is published online in the June 29, 2012 edition of Comptes Rendus Biologies, a publication of the French Academy of Sciences.
Sunday, May 20, 2012
Growth Factor in Stem Cells May Spur Recovery From MS
Source: Case Western Reserve University
Date: May 20, 2012
Summary:
CLEVELAND - A substance in human mesenchymal stem cells that promotes growth appears to spur restoration of nerves and their function in rodent models of multiple sclerosis (MS), researchers at Case Western Reserve University School of Medicine have found. Their study is embargoed until published in the online version of Nature Neuroscience at 1 p.m. U.S. Eastern Standard Time on Sunday, May 20. In animals injected with hepatocyte growth factor, inflammation declined and neural cells grew. Perhaps most important, the myelin sheath, which protects nerves and their ability to gather and send information, regrew, covering lesions caused by the disease. The research is published in the current issue of Nature Neuroscience.
In this study, the researchers first wanted to test whether the presence of stem cells or something cells produce promotes recovery. They injected mice with the medium in which mesenchymal stem cells, culled from bone marrow, grew. All 11 animals, which have a version of MS, showed a rapid reduction in functional deficits.
Date: May 20, 2012
Summary:
CLEVELAND - A substance in human mesenchymal stem cells that promotes growth appears to spur restoration of nerves and their function in rodent models of multiple sclerosis (MS), researchers at Case Western Reserve University School of Medicine have found. Their study is embargoed until published in the online version of Nature Neuroscience at 1 p.m. U.S. Eastern Standard Time on Sunday, May 20. In animals injected with hepatocyte growth factor, inflammation declined and neural cells grew. Perhaps most important, the myelin sheath, which protects nerves and their ability to gather and send information, regrew, covering lesions caused by the disease. The research is published in the current issue of Nature Neuroscience.
In this study, the researchers first wanted to test whether the presence of stem cells or something cells produce promotes recovery. They injected mice with the medium in which mesenchymal stem cells, culled from bone marrow, grew. All 11 animals, which have a version of MS, showed a rapid reduction in functional deficits.
Thursday, May 03, 2012
Aged Hematopoietic Stem Cells Rejuvenated to Be Functionally Younger
Source: Cincinnati Children's Hospital Medical Center
Date: May 3, 2012
Summary:
Researchers have rejuvenated aged hematopoietic stem cells to be functionally younger, offering intriguing clues into how medicine might one day fend off some ailments of old age. Scientists at Cincinnati Children’s Hospital Medical Center and the Ulm University Medicine in Germany report their findings online May 3 in the journal Cell Stem Cell. The paper brings new perspective to what has been a life science controversy – countering what used to be broad consensus that the aging of hematopoietic stem cells (HSCs) was locked in by nature and not reversible by therapeutic intervention.
The findings are early and involve laboratory manipulation of mouse cells, so it remains to be seen what direct application they may have for humans. Still, the study expands what is known about the basic molecular and cellular mechanisms of aging -- a necessary step to one day designing rational approaches to aiding a healthy aging process.
One reason the research team focused on Cdc42 is that previous studies have reported elevated activity of the protein in various tissue types of older mice -- which have a natural life span of around two years. Also, elevated expression of Cdc42 has been found in immune system white blood cells in older humans.
In the current study, researchers found elevated activity of Cdc42 in the HSCs of older mice. They also were able to induce premature aging of HSCs in mice by genetically increasing Cdc42 activity in the cells. The aged cells lost structural organization and polarity, resulting in improper placement and spacing of components inside the cells. This disorganization contributed to the cells' decreased functional efficiency.
Date: May 3, 2012
Summary:
Researchers have rejuvenated aged hematopoietic stem cells to be functionally younger, offering intriguing clues into how medicine might one day fend off some ailments of old age. Scientists at Cincinnati Children’s Hospital Medical Center and the Ulm University Medicine in Germany report their findings online May 3 in the journal Cell Stem Cell. The paper brings new perspective to what has been a life science controversy – countering what used to be broad consensus that the aging of hematopoietic stem cells (HSCs) was locked in by nature and not reversible by therapeutic intervention.
The findings are early and involve laboratory manipulation of mouse cells, so it remains to be seen what direct application they may have for humans. Still, the study expands what is known about the basic molecular and cellular mechanisms of aging -- a necessary step to one day designing rational approaches to aiding a healthy aging process.
One reason the research team focused on Cdc42 is that previous studies have reported elevated activity of the protein in various tissue types of older mice -- which have a natural life span of around two years. Also, elevated expression of Cdc42 has been found in immune system white blood cells in older humans.
In the current study, researchers found elevated activity of Cdc42 in the HSCs of older mice. They also were able to induce premature aging of HSCs in mice by genetically increasing Cdc42 activity in the cells. The aged cells lost structural organization and polarity, resulting in improper placement and spacing of components inside the cells. This disorganization contributed to the cells' decreased functional efficiency.
Monday, April 30, 2012
Improved Adult-Derived Human Stem Cells Have Fewer Genetic Changes Than Expected
Source: Johns Hopkins Medicine
Date: April 30, 2012
Summary:
A team of researchers from Johns Hopkins University and the National Human Genome Research Institute has evaluated the whole genomic sequence of stem cells derived from human bone marrow cells -- so-called induced pluripotent stem (iPS) cells -- and found that relatively few genetic changes occur during stem cell conversion by an improved method. The findings, reported in the March issue of Cell Stem Cell, the official journal of the International Society for Stem Cell Research (ISSCR), will be presented at the annual ISSCR meeting in June.
Each time a cell divides, it has the chance to make errors and incorporate new genetic changes in its DNA, Cheng explains. Some genetic changes can be harmless, but others can lead to changes in cell behavior that may lead to disease and, in the worst case, to cancer. In the new study, the researchers showed that iPS cells derived from adult bone marrow cells contain random genetic changes that do not specifically predispose the cells to form cancer.
Date: April 30, 2012
Summary:
A team of researchers from Johns Hopkins University and the National Human Genome Research Institute has evaluated the whole genomic sequence of stem cells derived from human bone marrow cells -- so-called induced pluripotent stem (iPS) cells -- and found that relatively few genetic changes occur during stem cell conversion by an improved method. The findings, reported in the March issue of Cell Stem Cell, the official journal of the International Society for Stem Cell Research (ISSCR), will be presented at the annual ISSCR meeting in June.
Each time a cell divides, it has the chance to make errors and incorporate new genetic changes in its DNA, Cheng explains. Some genetic changes can be harmless, but others can lead to changes in cell behavior that may lead to disease and, in the worst case, to cancer. In the new study, the researchers showed that iPS cells derived from adult bone marrow cells contain random genetic changes that do not specifically predispose the cells to form cancer.
Thursday, April 26, 2012
How Stem Cell Therapy Can Keep the Immune System Under Control
Source: University of Southern California
Date: April 26, 2012
Summary:
A new study, appearing in Cell Stem Cell and led by researchers at the University of Southern California, outlines the specifics of how autoimmune disorders can be controlled by infusions of mesenchymal stem cells (MSC). Highly versatile MSC originate from the mesoderm, or middle layer of tissue, in a developing embryo. MSC can be isolated from several kinds of human tissue, including bone marrow and the umbilical cord.
Date: April 26, 2012
Summary:
A new study, appearing in Cell Stem Cell and led by researchers at the University of Southern California, outlines the specifics of how autoimmune disorders can be controlled by infusions of mesenchymal stem cells (MSC). Highly versatile MSC originate from the mesoderm, or middle layer of tissue, in a developing embryo. MSC can be isolated from several kinds of human tissue, including bone marrow and the umbilical cord.
Wednesday, April 11, 2012
Stem Cells from Pelvic Bone May Preserve Heart Function
Source: Orlando Health
Date: April 11, 2012
Summary:
Stem cells from the pelvic bone may help hearts beat stronger. Doctors and other clinicians at the Orlando Health Heart Institute are researching the use of stem cells from pelvic bone marrow to restore tissue and improve heart function after muscle damage from heart attacks.
Date: April 11, 2012
Summary:
Stem cells from the pelvic bone may help hearts beat stronger. Doctors and other clinicians at the Orlando Health Heart Institute are researching the use of stem cells from pelvic bone marrow to restore tissue and improve heart function after muscle damage from heart attacks.
Saturday, March 24, 2012
Bone Marrow Stem Cells Can Improve Heart Function, Study Suggests
Source: Mayo Clinic
Date: March 24, 2012
Summary:
CHICAGO — A research network led by a Mayo Clinic physician found that stem cells derived from heart failure patients' own bone marrow and injected into their hearts improved the function of the left ventricle, the heart's pumping chamber. Researchers also found that certain types of the stem cells were associated with the largest improvement and warrant further study. The results were presented today at the 2012 American College of Cardiology Meeting in Chicago. They will also be published online in the Journal of the American Medical Association.
Date: March 24, 2012
Summary:
CHICAGO — A research network led by a Mayo Clinic physician found that stem cells derived from heart failure patients' own bone marrow and injected into their hearts improved the function of the left ventricle, the heart's pumping chamber. Researchers also found that certain types of the stem cells were associated with the largest improvement and warrant further study. The results were presented today at the 2012 American College of Cardiology Meeting in Chicago. They will also be published online in the Journal of the American Medical Association.
Tuesday, March 20, 2012
SANBIO ANNOUNCES ENROLLMENT OF FIRST COHORT OF PATIENTS IN ITS CLINICAL TRIAL OF STEM CELL THERAPY FOR CHRONIC STROKE
Source: SanBio Inc.
Date: March 20, 2012
Summary:
SanBio Inc. today announced the successful enrollment of the first dose cohort of patients in its Phase 1/2a clinical trial testing the safety and efficacy of a novel allogeneic stem cell therapy product, SB623, a cell therapy product consisting of cells derived from genetically engineered bone marrow stromal cells obtained from healthy adult donors, in patients suffering from chronic deficits resulting from previous stroke injuries. The first 6 patients, of a total of 18, have been successfully administered SB623. The trial is being conducted at Stanford University and the University of Pittsburgh. No safety concerns have been reported. Details of this clinical trial can be found here.
Date: March 20, 2012
Summary:
SanBio Inc. today announced the successful enrollment of the first dose cohort of patients in its Phase 1/2a clinical trial testing the safety and efficacy of a novel allogeneic stem cell therapy product, SB623, a cell therapy product consisting of cells derived from genetically engineered bone marrow stromal cells obtained from healthy adult donors, in patients suffering from chronic deficits resulting from previous stroke injuries. The first 6 patients, of a total of 18, have been successfully administered SB623. The trial is being conducted at Stanford University and the University of Pittsburgh. No safety concerns have been reported. Details of this clinical trial can be found here.
Tuesday, March 06, 2012
Investigational human adult stem cell therapy studied in ischemic stroke patients
Source: Methodist Hospital, Houston
Date: March 6, 2012
Summary:
Houston, TX - Physicians at the Methodist Neurological Institute are studying the use of human stem cells as a possible treatment for acute ischemic stroke, a leading cause of death and disability. Each year, stroke affects more than 15 million people around the world. Patients whose ischemic strokes occur within one to two days of being admitted to The Methodist Hospital in Houston may be eligible to enroll in the double-blind, randomized, placebo-controlled phase 2 safety and efficacy trial of MultiStem®, a novel therapy being developed by Athersys, Inc.
The study will examine the effects of intravenous administration of adult stem cells that can be manufactured from a donor. In contrast to traditional bone marrow transplants, which require one donor for each patient that needs treatment, MultiStem is a patented formulation of early adult stem cells, and hundreds of thousands to millions of doses can be made from the bone marrow cells of one healthy donor. The product can be made in advance, and may be stored in the hospital and used “off the shelf”.
Researchers in the clinical trial will not only look at how well the investigational therapy works for stroke treatment, but they will also monitor for potential side effects and how potent the drug is compared to placebo.
Another goal of this study is to examine some of the stem cells’ effects on organs such as the spleen, which is thought to contribute to ongoing inflammation that could increase brain injury after the initial stroke. Published work from preclinical studies shows that MultiStem can provide benefits even when administered several days after a stroke has occurred, and some of the cell effects appear to occur through their action on the spleen. Animal models used in this research showed a statistically significant and durable improvement in motor skills relative to animals that received a placebo.
Date: March 6, 2012
Summary:
Houston, TX - Physicians at the Methodist Neurological Institute are studying the use of human stem cells as a possible treatment for acute ischemic stroke, a leading cause of death and disability. Each year, stroke affects more than 15 million people around the world. Patients whose ischemic strokes occur within one to two days of being admitted to The Methodist Hospital in Houston may be eligible to enroll in the double-blind, randomized, placebo-controlled phase 2 safety and efficacy trial of MultiStem®, a novel therapy being developed by Athersys, Inc.
The study will examine the effects of intravenous administration of adult stem cells that can be manufactured from a donor. In contrast to traditional bone marrow transplants, which require one donor for each patient that needs treatment, MultiStem is a patented formulation of early adult stem cells, and hundreds of thousands to millions of doses can be made from the bone marrow cells of one healthy donor. The product can be made in advance, and may be stored in the hospital and used “off the shelf”.
Researchers in the clinical trial will not only look at how well the investigational therapy works for stroke treatment, but they will also monitor for potential side effects and how potent the drug is compared to placebo.
Another goal of this study is to examine some of the stem cells’ effects on organs such as the spleen, which is thought to contribute to ongoing inflammation that could increase brain injury after the initial stroke. Published work from preclinical studies shows that MultiStem can provide benefits even when administered several days after a stroke has occurred, and some of the cell effects appear to occur through their action on the spleen. Animal models used in this research showed a statistically significant and durable improvement in motor skills relative to animals that received a placebo.
Wednesday, February 01, 2012
Encouraging Results With Stem Cell Transplant for Brain Injury
Source: Wolters Kluwer Health: Lippincott Williams & Wilkins
Date: February 1, 2012
Summary:
Experiments in brain-injured rats show that stem cells injected via the carotid artery travel directly to the brain, where they greatly enhance functional recovery, reports a study in the February issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Researchers evaluated a new "intra-arterial" technique of stem cell transplantation in rats. Within seven days after induced TBI, stem cells created from the rats' bone marrow were injected into the carotid artery. The goal was to deliver the stem cells directly to the brain, without having them travel through the general circulation.
Before injection, the stem cells were labeled with "quantum dots" -- a biocompatible, fluorescent semiconductor created using nanotechnology. The quantum dots emit near-infrared light, with much longer wavelengths that penetrate bone and skin. This allowed the researchers to noninvasively monitor the stem cells for four weeks after transplantation.
Using this in vivo optical imaging technique, Dr Osanai and colleagues were able to see that the injected stem cells entered the brain on the "first pass," without entering the general circulation. Within three hours, the stem cells began to migrate from the smallest brain blood vessels (capillaries) into the area of brain injury.
After four weeks, rats treated with stem cells had significant recovery of motor function (movement), while untreated rats had no recovery. Examination of the treated brains confirmed that the stem cells had transformed into different types of brain cells and participated in healing of the injured brain area.
Date: February 1, 2012
Summary:
Experiments in brain-injured rats show that stem cells injected via the carotid artery travel directly to the brain, where they greatly enhance functional recovery, reports a study in the February issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Researchers evaluated a new "intra-arterial" technique of stem cell transplantation in rats. Within seven days after induced TBI, stem cells created from the rats' bone marrow were injected into the carotid artery. The goal was to deliver the stem cells directly to the brain, without having them travel through the general circulation.
Before injection, the stem cells were labeled with "quantum dots" -- a biocompatible, fluorescent semiconductor created using nanotechnology. The quantum dots emit near-infrared light, with much longer wavelengths that penetrate bone and skin. This allowed the researchers to noninvasively monitor the stem cells for four weeks after transplantation.
Using this in vivo optical imaging technique, Dr Osanai and colleagues were able to see that the injected stem cells entered the brain on the "first pass," without entering the general circulation. Within three hours, the stem cells began to migrate from the smallest brain blood vessels (capillaries) into the area of brain injury.
After four weeks, rats treated with stem cells had significant recovery of motor function (movement), while untreated rats had no recovery. Examination of the treated brains confirmed that the stem cells had transformed into different types of brain cells and participated in healing of the injured brain area.
Friday, January 27, 2012
Scientists perform Ontario's first cardiac stem cell transplant
Source: University of Toronto
Date: January 27, 2012
Summary:
University of Toronto faculty members performed the first cardiac stem cell transplant in Ontario recently, using stem cells derived from the patient's own bone marrow, isolated completely within the operating room, and implanted into the heart at the time of coronary bypass surgery. The stem cells were injected following coronary artery bypass graft (CABG) surgery, by a multi-disciplinary team led by Dr. Terrence Yau, a U of T professor of surgery and director of the Cardiac Stem Cell Therapy Program at the hospital’s Peter Munk Cardiac Centre, part of the University Health Network (UHN).
The Toronto Star published a news story on the trial yesterday.
Date: January 27, 2012
Summary:
University of Toronto faculty members performed the first cardiac stem cell transplant in Ontario recently, using stem cells derived from the patient's own bone marrow, isolated completely within the operating room, and implanted into the heart at the time of coronary bypass surgery. The stem cells were injected following coronary artery bypass graft (CABG) surgery, by a multi-disciplinary team led by Dr. Terrence Yau, a U of T professor of surgery and director of the Cardiac Stem Cell Therapy Program at the hospital’s Peter Munk Cardiac Centre, part of the University Health Network (UHN).
The Toronto Star published a news story on the trial yesterday.
Monday, November 14, 2011
Stem Cell Study Helps Clarify the Best Time for Therapy to Aid Heart Attack Survivors
Source: Mayo Clinic
Date: November 14, 2011
Summary:
ORLANDO, Fla. — A research network led by a Mayo Clinic physician found that stem cells obtained from bone marrow delivered two to three weeks after a person has a heart attack did not improve heart function. This is the first study to systematically examine the timing and method of stem cell delivery and provides vital information for the field of cell therapy. The results were presented this morning at the 2011 Scientific Sessions of the American Heart Association Meeting in Orlando, Fla. They also will be published online in JAMA to coincide with the presentation.
Date: November 14, 2011
Summary:
ORLANDO, Fla. — A research network led by a Mayo Clinic physician found that stem cells obtained from bone marrow delivered two to three weeks after a person has a heart attack did not improve heart function. This is the first study to systematically examine the timing and method of stem cell delivery and provides vital information for the field of cell therapy. The results were presented this morning at the 2011 Scientific Sessions of the American Heart Association Meeting in Orlando, Fla. They also will be published online in JAMA to coincide with the presentation.
Results of trial using adult stem cells for heart failure triple researchers’ projections
Source: Brigham and Women's Hospital
Date: November 14, 2011
Summary:
ORLANDO, Fla. – Patients suffering from heart failure due to a previous myocardial infarction showed an average of 12 percent improvement one year following an investigative treatment that involved infusing them with their own stem cells. The results triple the 4 percent improvement average the researchers projected for the Phase I trial.
Results of the trial are published today (Nov. 14) in The Lancet and concurrently presented at the American Heart Association Scientific Sessions in Orlando, Fla. They are the first report of administering subjects’ own cardiac stem cells in humans; previous studies have used stem cells harvested from bone marrow.
Date: November 14, 2011
Summary:
ORLANDO, Fla. – Patients suffering from heart failure due to a previous myocardial infarction showed an average of 12 percent improvement one year following an investigative treatment that involved infusing them with their own stem cells. The results triple the 4 percent improvement average the researchers projected for the Phase I trial.
Results of the trial are published today (Nov. 14) in The Lancet and concurrently presented at the American Heart Association Scientific Sessions in Orlando, Fla. They are the first report of administering subjects’ own cardiac stem cells in humans; previous studies have used stem cells harvested from bone marrow.
Phase I trial shows adult stem cell heart treatment three times more effective than expected
Source: University of Louisville
Posted: November 14, 2011 09:03 AM
Summary:
Patients who suffered from heart failure due to a heart attack showed an average of 12 percent improvement in heart function one year after they underwent an investigative treatment that involved infusing them with their own stem cells. Pre-trial projections were for a 4 percent improvement average. University of Louisville researcher Roberto Bolli, the lead investigator on the Phase I clinical trial, will present the findings today at the American Heart Association Scientific Sessions in Orlando, Fla. He also is lead author on a paper set for publication today in The Lancet.
Posted: November 14, 2011 09:03 AM
Summary:
Patients who suffered from heart failure due to a heart attack showed an average of 12 percent improvement in heart function one year after they underwent an investigative treatment that involved infusing them with their own stem cells. Pre-trial projections were for a 4 percent improvement average. University of Louisville researcher Roberto Bolli, the lead investigator on the Phase I clinical trial, will present the findings today at the American Heart Association Scientific Sessions in Orlando, Fla. He also is lead author on a paper set for publication today in The Lancet.
Tuesday, October 11, 2011
"STIMULATED" STEM CELLS STOP DONOR ORGAN REJECTION
Source: Johns Hopkins Medical Institutions
Date: October 11, 2011
Summary:
Johns Hopkins researchers have developed a way to stimulate a rat’s stem cells after a liver transplant as a means of preventing rejection of the new organ without the need for lifelong immunosuppressant drugs. The need for anti-rejection medicines, which carry serious side effects, is a major obstacle to successful long-term transplant survival in people
With a combination of a very low, short-term dose of an immunosuppressive drug to prevent immediate rejection and four doses of a medication that frees the recipient’s stem cells from the bone marrow to seek out and populate the donor organ, the rats lived more than 180 days with good liver function despite stopping both drugs after one week. The researchers are also testing the method on other transplanted organs, including kidneys, in rats and other larger animals.
Essentially, the Hopkins scientists transformed the donor liver from a foreign object under attack by the rat’s immune system into an organ tolerated by the recipient’s immune system — all in a matter of three months from the date of transplant, they report.
The technique, if replicated in humans, could mark a major shift in the process of organ transplantation, the researchers say. An article describing the experiment appears in the current issue of the American Journal of Transplantation.
Date: October 11, 2011
Summary:
Johns Hopkins researchers have developed a way to stimulate a rat’s stem cells after a liver transplant as a means of preventing rejection of the new organ without the need for lifelong immunosuppressant drugs. The need for anti-rejection medicines, which carry serious side effects, is a major obstacle to successful long-term transplant survival in people
With a combination of a very low, short-term dose of an immunosuppressive drug to prevent immediate rejection and four doses of a medication that frees the recipient’s stem cells from the bone marrow to seek out and populate the donor organ, the rats lived more than 180 days with good liver function despite stopping both drugs after one week. The researchers are also testing the method on other transplanted organs, including kidneys, in rats and other larger animals.
Essentially, the Hopkins scientists transformed the donor liver from a foreign object under attack by the rat’s immune system into an organ tolerated by the recipient’s immune system — all in a matter of three months from the date of transplant, they report.
The technique, if replicated in humans, could mark a major shift in the process of organ transplantation, the researchers say. An article describing the experiment appears in the current issue of the American Journal of Transplantation.
Tuesday, September 20, 2011
Using Bone Marrow to Protect the Brain: Stem Cell Technology Begins Clinical Trial for Lou Gehrig's Disease
Source: American Friends of Tel Aviv University
Date: September 20, 2011
Summary:
Through a clinical product called NurOwn, researchers at Tel Aviv University are turning bone marrow stem cells into astrocyte-like cells which are responsible for the well-being of the brain's neurons. Trials for the technology, which has the potential to treat a broad range of neurodegenerative conditions, are now planned for Massachusetts General Hospital.
the technology is now a patent-pending process that takes stem cells from a patient's own bone marrow and causes them to differentiate into astrocyte-like cells, which are responsible for the well-being of the brain's neurons. The cells release neurotrophic factors, or neuroprotectants, which have been shown to play a key role in reducing the progress of ALS, a debilitating disease characterized by the progressive degeneration of motor neurons, resulting in paralysis of a patient's limbs and organ function.
The research has appeared in the Journal of Stem Cells Reviews and Reports and a number of other publications.
Date: September 20, 2011
Summary:
Through a clinical product called NurOwn, researchers at Tel Aviv University are turning bone marrow stem cells into astrocyte-like cells which are responsible for the well-being of the brain's neurons. Trials for the technology, which has the potential to treat a broad range of neurodegenerative conditions, are now planned for Massachusetts General Hospital.
the technology is now a patent-pending process that takes stem cells from a patient's own bone marrow and causes them to differentiate into astrocyte-like cells, which are responsible for the well-being of the brain's neurons. The cells release neurotrophic factors, or neuroprotectants, which have been shown to play a key role in reducing the progress of ALS, a debilitating disease characterized by the progressive degeneration of motor neurons, resulting in paralysis of a patient's limbs and organ function.
The research has appeared in the Journal of Stem Cells Reviews and Reports and a number of other publications.
Subscribe to:
Posts (Atom)